Ensysce Bioscience CEO Dr. Lynn Kirkpatrick joined Steve Darling from Proactive to share more details about the company that has proprietary technology platforms with the hopes of safer prescription drugs. The company does that through its Trypsin-Activated Abuse Protection and Multi-Pill Abuse Resistance platforms. The key is the drug can only be activated or turned on when it is swallowed and comes into contact with the natural digestive enzyme trypsin, which is found in the small intestine.
Kirkpatrick telling Proactive more about the platforms and also about its Clinical trials which have shown promising results. Ensysce also plans to initiate a phase three trial and seek FDA approval. The company's goal is to address the opioid crisis by offering effective pain relief while minimizing the risk of addiction and abuse.